<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079858</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-61</org_study_id>
    <nct_id>NCT01079858</nct_id>
  </id_info>
  <brief_title>Evaluation of FID 114657 in Dry Eye Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the overall Meibomian Gland Dysfunction
      Subject's preference for a particular product. Dry eye symptom relief will also be evaluated
      based on clinical evaluation and a set of subject questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preference based on subject's relief of dry eye</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>FID 114657 (ORB Preserved Ocular Emulsion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID 114657 (ORB Preserved Ocular Emulsion)</intervention_name>
    <description>Patients will dose as needed throughout the day (PRN) for 4 weeks.</description>
    <arm_group_label>FID 114657 (ORB Preserved Ocular Emulsion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age

          -  must read and sign the informed consent forms (ICF)

          -  must agree to comply with the study requirements.

          -  Patients must have a best corrected visual acuity of 0.6 LogMar or better in each eye

          -  must report having an ocular examination in the last two years

          -  must be using topical ocular dry eye therapy (artificial tears or RestasisÂ® at least 2
             times per day.

          -  must have been diagnosed with Meibomian Gland Dysfunction / Posterior Blepharitis
             based on the following criteria: must have dry eye symptoms and Meibomian gland
             expression grade greater than 1.

        Exclusion Criteria:

          -  Patients cannot wear contact lenses during the study and cannot have a history of
             hypersensitivity to any component of FID 114657.

          -  Patients cannot have ocular or intraocular surgery or serious ocular trauma within the
             past 6 months, and cannot have a history and/or current evidence of active intraocular
             inflammation in either eye.

          -  Patients cannot have punctal plugs that were placed less than or equal to 30 days
             prior to Visit 1, and they cannot have ocular conditions that, in the opinion of the
             investigator, preclude the safe administration of the test article.

          -  They cannot have started or changed the dose of chronic systemic medication within 7
             days prior to visit 1, and must remain on a stable dosing regimen for the duration of
             the study.

          -  Patients cannot have participated in another investigational clinical or research
             study within 30 days of visit 1.

          -  Subjects cannot have a history and/or current evidence of the following: epithelial
             herpes simplex keratitis (dendritic keratitis); vaccinia, active or recent varicella
             viral disease of the cornea and/or conjunctiva; active ocular rosacea (excluding
             subjects enrolled with MGD (posterior blepharitis)); acute or chronic bacterial
             disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of
             the eye; and/or fungal diseases of the eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>Dry Eye</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

